Skip to main content
. Author manuscript; available in PMC: 2021 Oct 9.
Published in final edited form as: ACS Infect Dis. 2020 Sep 21;6(10):2616–2628. doi: 10.1021/acsinfecdis.0c00217

Figure 1.

Figure 1.

Inhibition of the NS2B–NS3 interactions and protease activity. (A) Dose-dependent inhibition of SLC upon binding of NLuc-NS2B49–66 to GST-CLuc-NS3 by JMX0207. N =3. (B) Dose–response inhibitions of the DENV2 His-NS2B/His-MBP-NS3 protease activity by JMX0207. N = 3. In both (A) and (B), the DMSO control was set as 100%. The values represent means ± standard deviation (SD) in all panels.